Ciforadenant (CPI-444)
Cancer
Phase 1/2Completed (Development status unclear)
Key Facts
Indication
Cancer
Phase
Phase 1/2
Status
Completed (Development status unclear)
Company
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is focused on developing precisely-targeted medicines for difficult-to-treat cancers and immune diseases, with a core platform centered on ITK inhibition. Founded in 2014, the company has advanced its lead candidate, soquelitinib, through Phase 1 trials and maintains a broader clinical pipeline including ciforadenant and mupadolimab. Led by industry veterans who previously developed Rituxan and Imbruvica, Corvus leverages a biomarker-driven, clinical science approach to increase development success and is publicly traded on NASDAQ.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Shared Antigen mRNA Cancer Vaccines | BioNTech | Phase 2 |
| Targeted Oncology Therapies | BioNTech | Phase 1/2 |
| ARGX-119 | Argenx | Phase 1 |
| Oncology Program | Shionogi | Clinical |
| Bmab (Bevacizumab) | Biocon | Approved |
| Mupadolimab (CPI-006) | Corvus Pharmaceuticals | Phase 1 |
| tovecimig | Compass Therapeutics | Clinical |
| CTX-8371 | Compass Therapeutics | Clinical |
| XmAb 14045 | Xencor | Clinical |
| XmAb 13676 | Xencor | Clinical |
| Vibostolimab | Xencor | Clinical |
| PB272 (neratinib, intravenous) | Puma Biotechnology | Not Disclosed |